Research article | Open | Open Peer Review | Published:
Testing the thrifty gene hypothesis: the Gly482Ser variant in PPARGC1Ais associated with BMI in Tongans
BMC Medical Geneticsvolume 12, Article number: 10 (2011)
The thrifty gene hypothesis posits that, in populations that experienced periods of feast and famine, natural selection favoured individuals carrying thrifty alleles that promote the storage of fat and energy. Polynesians likely experienced long periods of cold stress and starvation during their settlement of the Pacific and today have high rates of obesity and type 2 diabetes (T2DM), possibly due to past positive selection for thrifty alleles. Alternatively, T2DM risk alleles may simply have drifted to high frequency in Polynesians. To identify thrifty alleles in Polynesians, we previously examined evidence of positive selection on T2DM-associated SNPs and identified a T2DM risk allele at unusually high frequency in Polynesians. We suggested that the risk allele of the Gly482Ser variant in the PPARGC1A gene was driven to high frequency in Polynesians by positive selection and therefore possibly represented a thrifty allele in the Pacific.
Here we examine whether PPARGC1A is a thrifty gene in Pacific populations by testing for an association between Gly482Ser genotypes and BMI in two Pacific populations (Maori and Tongans) and by evaluating the frequency of the risk allele of the Gly482Ser variant in a sample of worldwide populations.
We find that the Gly482Ser variant is associated with BMI in Tongans but not in Maori. In a sample of 58 populations worldwide, we also show that the 482Ser risk allele reaches its highest frequency in the Pacific.
The association between Gly482Ser genotypes and BMI in Tongans together with the worldwide frequency distribution of the Gly482Ser risk allele suggests that PPARGC1A remains a candidate thrifty gene in Pacific populations.
The prevalence of type 2 diabetes mellitus (T2DM) in Polynesians is among the highest in the world, reaching 40% among adults on some islands [1–3]. The thrifty gene hypothesis  offers a possible explanation for the high prevalence of T2DM in the Pacific. This hypothesis suggests that populations whose ancestral environments were characterized by periods of feast and famine experienced positive selection for alleles that promote the storage of fat and energy. Moreover, under modern conditions, populations with such thrifty metabolisms are expected to have high rates of T2DM and related traits (e.g. obesity). The ancestors of present-day Polynesians embarked on long open ocean voyages and are believed to have been exposed to cold stress and starvation during their settlement of the Pacific. Such conditions may have driven thrifty alleles to high frequency in Polynesians, thereby explaining the high prevalence of T2DM and obesity in Polynesia today [5–7].
According to this hypothesis, T2DM risk alleles at unusually high frequencies in Polynesians would represent strong candidate thrifty alleles: they may have been driven to high frequency by positive selection, thereby accounting for the high prevalence of T2DM in Polynesia. Alternatively, T2DM risk alleles may have existed as neutral alleles in the ancestors of Polynesians, and then increased in frequency in Polynesia via genetic drift, especially as a consequence of founder effects and bottleneck events. It is well-established that the ancestors of Polynesians migrated out of Taiwan through island southeast Asia and coastal and island Melanesia [8, 9], and that this migration was accompanied by admixture with Melanesians and by severe reductions in genetic variation [10–13]. Such decreases in population size could have elevated the frequency of neutral T2DM risk alleles in Polynesians by chance, which then only became detrimental when Polynesians adopted a more Western diet.
Under either hypothesis, the frequency of causal T2DM risk alleles in Polynesians should be elevated, relative to their ancestral populations (East Asians and Melanesians). We therefore previously undertook an evolutionary genetics approach and genotyped 10 T2DM-associated single nucleotide polymorphisms (SNPs) in samples of Polynesian, Chinese, and New Guinean origin, without any associated phenotype information . We identified the risk allele of the Gly482Ser SNP (rs8192678) in the PPARGC1A gene as a potential thrifty allele as it had a frequency of 0.717 in Polynesians but was absent in New Guineans. Such a striking difference in frequency was observed in less than 1% of ~90,000 SNPs genotyped in the same samples. Thus, we proposed that the high frequency of the PPARGC1A risk allele in Polynesians may contribute to the high prevalence of T2DM and T2DM-related phenotypes in Polynesians.
PPARGC1A plays a pivotal role in insulin signaling, mitochondrial regulation and adaptive thermogenesis [15–17] and is a reasonable thrifty gene candidate as it integrates metabolic pathways that support mammalian survival during prolonged starvation or hibernation [18, 19]. The T2DM risk allele at PPARGC1A changes a glycine to serine at codon 482. The Gly482Ser SNP appears to be functional as transfection assays have demonstrated that it affects the protein's efficiency as a coactivator on the Tfam promoter  and 482Ser carriers were shown to have 60% less PPARGC1A expression in skeletal muscle than noncarriers . Associations between Gly482Ser and T2DM-related phenotypes have been reported in several populations [22–28], but the absence of significant associations has also been reported [29–33]. In the present study, we further test the thrifty gene hypothesis in Pacific populations by examining the relationship between Gly482Ser genotypes and body mass index (BMI) in Maori and Tongans and by comparing the frequency of the 482Ser risk allele in Pacific populations to populations worldwide.
Written informed consent was obtained from all participants in the present study. For the Tongans, ethics approval was obtained from the Research Ethics Committee of the Faculty of Medicine at the University of Tokyo and the Graduate School of Comprehensive Human Sciences at University of Tsukuba. For the Maori, ethics approval was obtained from the Multiregional Ethics Committee of New Zealand as part of the Rakaipaaka Health and Ancestry Study (Ethics application MEC022005) and ethical clearance was granted by the tribal organisation (Te Iwi o Rakaipaaka Inc.).
Genotype data from the Gly482Ser SNP from Cook Islanders, Western Samoans, Nuie Islanders and New Guineans (non-CEPH panel samples) was obtained from Myles et al. . Atypical and related individuals from the Human Genome Diversity Panel of the Centre D'Etude du Polymorphisme Humain (CEPH-HGDP) were removed, which resulted in 952 individuals from 53 populations [34, 35]. Genotyping of the Gly482Ser SNP (dbSNP ID rs8192678) in the CEPH-HGDP and the Tikopian samples was done according to the procedure described in Myles et al. . The Tongan samples were genotyped with a TaqMan assay.
New Zealand DNA samples were collected from indigenous Maori individuals residing in the North Island as part of a community health survey. Individuals were unrelated by first degree, had two Maori parents by self-report, and belonged to one segment of the wider Maori population. DNA was extracted from blood using Qiagen kits and the Gly482Ser SNP was genotyped using the Sequenom platform. Evidence of association between body mass index, age, sex, population, and genotype were analysed using ANOVA and multiple regression in R.
The association analysis was performed in two Pacific populations for which BMI measures were available: Tongans and Maori. Details of the cohorts and the results of the association analysis between Gly482Ser genotypes and BMI are presented in Table 1. The mean BMI values in the Tongan (34.0 kg/m2) and the Maori (32.1 kg/m2) samples fall within the range of "Obesity class I" according to the World Health Organization  and are similar to BMI values observed in other Pacific populations [37–39]. We find that BMI is significantly higher in Tongans than in the Maori (two-sided t-test, P = 0.033). The frequency of the 482Ser risk allele is higher in Maori (0.833) than in Tongans (0.592).
It is unclear from previous studies through what mode of inheritance (e.g. dominance, co-dominance or recessive) the Gly482Ser most likely acts. We therefore present results from all three possible modes of inheritance in Table 1. Age and sex were included as covariates when assessing associations within each population. We compared the results from a multiple linear regression model with age, sex and population as factors and BMI as the dependent variable to a model including only age and sex using an F test and found that the two models differed significantly (P = 0.0183). Thus, in assessing the relationship between the Gly482Ser genotypes and BMI using multiple regression, we performed the association within each population separately. When the analysis was performed on all of the samples together, population was included as a covariate.
Gly482Ser genotypes showed no effect on age and sex adjusted BMI in the Maori, regardless of the mode of inheritance assumed (Table 1). In the Tongans, however, the 482Ser risk allele was significantly associated with age and sex adjusted BMI under both a co-dominance model (effect estimate = 1.397 kg/m2, P = 0.037) and a dominance model (effect estimate = 2.341 kg/m2, P = 0.014), while no significant effect was observed in Tongans under a recessive model (P = 0.46). When the two populations were combined, Gly482Ser genotypes showed no effect on age and sex adjusted BMI under any of the three modes of inheritance (Table 1). We present the effect estimates and their standard errors for a co-dominance model in Figure 1.
The allele frequencies of the 482Ser risk allele across 58 worldwide populations, including the Tongans and Maori from the present study, are presented in Figure 2. The geographic locations, sample sizes, genotype frequencies, allele frequencies and the P values from Hardy-Weinberg equilibrium tests for these 58 populations are presented in Additional File 1, Table S1. The Gly482Ser SNP was in Hardy-Weinberg equilibrium in all populations tested. The frequency of the 482Ser risk allele varies widely worldwide: it is completely absent in most of Africa and in New Guinea but reaches a frequency of 0.85 in Western Samoan and Niue Islanders (Figure 2). Throughout Europe, East Asia and the Americas, the risk allele is generally found at either low or intermediate frequencies. The highest frequencies of the risk allele are observed in Polynesians.
Disease risk alleles with large frequency differences between populations may account for large differences in the prevalence of diseases between populations . In some cases, large risk allele frequency differences between populations may be the result of local positive selection [41, 42], as predicted by the thrifty gene hypothesis . We previously identified the T2DM risk allele of the Gly482Ser variant in the PPARGC1A gene as a potential thrifty allele because of its unusually high frequency in Polynesians . In the present study, we further test the thrifty gene hypothesis in Polynesians by evaluating the association between the 482Ser risk allele and a T2DM-related phenotype, BMI, in Tongans and Maori. We find that the 482Ser risk allele is associated with age and sex adjusted BMI in Tongans assuming a dominance (P = 0.014) or a co-dominance model (P = 0.037), but not a recessive model of inheritance (P = 0.46). In the Maori, however, we found no significant associations between Gly482Ser genotypes and age and sex adjusted BMI (Table 1 and Figure 1). When considering the populations together and including population as a covariate, we also find no evidence of association (P = 0.56). Despite having a lower BMI, we find that the Maori have a higher PPARGC1A risk allele frequency than the Tongans. Although this observation does not support a causal relationship between the PPARGC1A risk allele and BMI, it can be explained by several confounding factors including sampling biases and environmental differences between populations.
Previous association studies between Gly482Ser and T2DM-related phenotypes have produced conflicting results, with some studies detecting significant effects [22–28] and others failing to detect effects [29–33]. These conflicting results and the differences in effect between populations observed in the present study may be the result of genetic by environment interactions or population-specific epistatic effects. It is worth noting that genome-wide association (GWA) studies have failed to detect associations between SNPs in or near PPARGC1A and T2DM [43–48] or BMI . To date, however, these GWA studies have been restricted to populations relatively distantly related to Pacific populations. Moreover, in the present study, the lack of an association in Maori could be the result of reduced statistical power compared to Tongans due to the smaller sample size (N = 110) and the high risk allele frequency (0.833) in Maori. Our results provide some support for the involvement of the PPARGC1A Gly482Ser SNP in body weight or the pathophysiology of obesity related phenotypes in Pacific populations, but large-scale GWA studies in Pacific populations are desired to test this association more robustly.
If the 482Ser risk allele was driven to high frequency in Polynesians by positive selection, we expect its frequency to be relatively high in Polynesians compared to other populations. We previously showed that the 482Ser risk allele is found at unusually high frequency in a sample of Polynesians compared to a sample of highland New Guineans . Here we extend the genotyping of this SNP to a worldwide sample and find that the highest frequencies of the 482Ser risk allele worldwide are indeed observed in Polynesian populations (Figure 2). One striking feature of the worldwide risk allele frequency distribution is the almost complete absence of the risk allele in Africa: we observe only three Gly482Ser heterozygotes out of 106 African individuals resulting in an allele frequency of only 0.01 in Africa (Figure 2 and Additional File 1, Table S1). Outside of Africa, the risk allele is generally found at intermediate frequencies: 0.36 in Europe; 0.33 in the Middle East; 0.27 in Central and South Asia; 0.39 in East Asia; and 0.25 in the Americas. The exception to this pattern is in Oceania where only a single heterozygote from Bougainville was observed among 53 Melanesians while the risk allele is found at a frequency of 0.69 among Polynesians (Figure 2 and Additional File 1, Table S1). The highest frequency of the risk allele worldwide is 0.85 and is found in Western Samoan and Niue Islanders. Such a striking difference in frequency between Melanesians and Polynesians is consistent with our previous observations  and suggests that local positive selection may be responsible for the increase in frequency of the risk allele in Polynesians. Alternatively, the non-risk allele may have gone to fixation due to selection in Melanesians. To determine whether the observed pattern is in fact due to positive selection, or whether it is the result of demographic effects such as a population bottleneck , will require more formal tests of selection at this locus.
It is worth noting that the search for thrifty alleles in Polynesians has not been restricted to the PPARGC1A gene. For example, it was recently shown that the Q223R (rs1137101) variant in the leptin receptor gene (LEPR) is associated with BMI and obesity in Pacific Islanders and thus represents a candidate thrifty locus . However, the frequency of the 223Q risk allele in Polynesians (0.10) is relatively low: 40 of 54 worldwide populations have higher frequencies of the risk allele than Polynesians . This observation suggests that the 223Q risk allele in LEPR did not rise in frequency in the Pacific due to selection and is thus unlikely to account for the unusually high prevalence of T2DM and obesity-related phenotypes in Polynesians.
The FTO gene was also evaluated as a candidate thrifty gene in Polynesians. Recent GWA studies conducted in populations of European origin have identified several SNPs associated with BMI in the FTO gene [52–54]. In Pacific populations, however, no association was detected between FTO risk alleles and BMI . In addition, the FTO risk alleles are not at unusually high frequency in the Pacific . These observations suggest that FTO is also unlikely to be a thrifty gene in Pacific populations.
The thrifty gene hypothesis is an oft-cited but often untested hypothesis that provides an evolutionary explanation for contemporary patterns of disease prevalence across human populations. Our finding that Gly482Ser genotypes in the PPARGC1A gene are associated with BMI in a Pacific population together with the observation that the frequencies of the 482Ser risk allele are highest in Polynesians, suggest that PPARGC1A remains a strong candidate thrifty gene in the Pacific. Moreover, PPARGC1A was originally identified as a possible candidate thrifty gene in Polynesians by purely genetic methods, without any associated phenotypic data ; the fact that Gly482Ser is associated with BMI in Tongans supports the utility of such approaches for identifying potential candidate genes.
The authors declare that they have no competing interests.
SM and MS designed the study. RAL, GKC, DPM and DAE provided genotype data from the Maori. JO, IN, RK, TI and YM provided genotype data from the Tongans. JGW, EH and JE provided the remaining genotype data. SM performed analyses. SM and MS wrote the manuscript. All authors read and approved the final manuscript.
Dowse G, Zimmet P, Finch C, Collins V: Decline in incidence of epidemic glucose intolerance in Nauruans: implications for the "thrifty genotype". Am J Epidemiology. 1991, 133: 1093-1104.
Zimmet P, Taft P, Guinea A, Guthrie W, Thoma K: The high prevalence of diabetes mellitus on a Central Pacific Island. Diabetologia. 1977, 13: 111-115. 10.1007/BF00745137.
Zimmet PZ, Dowse GK, Finch C, Serjeantson S, King H: The epidemiology and natural history of NIDDM--lessons from the South Pacific. Diabetes Metab Rev. 1990, 6: 91-124. 10.1002/dmr.5610060203.
Neel JV: Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"?. Bulletin of the WHO. 1962, 77 (8): 694-703.
Houghton P: The adaptive significance of Polynesian body form. Ann Human Biol. 1990, 17: 19-32. 10.1080/03014469000000752.
Baker P: Migrations, genetics, and the degenerative diseases of South Pacific Islanders. Migration and Mobility. Edited by: Boyce AJ. 1984, London: Taylor and Francis, 209-239.
Bindon JR, Baker PT: Bergmann's rule and the thrifty genotype. Am J Phys Anthropol. 1997, 104 (2): 201-210. 10.1002/(SICI)1096-8644(199710)104:2<201::AID-AJPA6>3.0.CO;2-0.
Gray RD, Drummond AJ, Greenhill SJ: Language Phylogenies Reveal Expansion Pulses and Pauses in Pacific Settlement. Science. 2009, 323 (5913): 479-483. 10.1126/science.1166858.
Moodley Y, Linz B, Yamaoka Y, Windsor HM, Breurec S, Wu J-Y, Maady A, Bernhoft S, Thiberge J-M, Phuanukoonnon S, et al: The Peopling of the Pacific from a Bacterial Perspective. Science. 2009, 323 (5913): 527-530. 10.1126/science.1166083.
Kayser M, Brauer S, Weiss G, Underhill PA, Roewer L, Schiefenhovel W, Stoneking M: Melanesian origin of Polynesian Y chromosomes. Curr Biol. 2000, 10 (20): 1237-1246. 10.1016/S0960-9822(00)00734-X.
Kayser M, Choi Y, van Oven M, Mona S, Brauer S, Trent RJ, Suarkia D, Schiefenhovel W, Stoneking M: The Impact of the Austronesian Expansion: Evidence from mtDNA and Y Chromosome Diversity in the Admiralty Islands of Melanesia. Mol Biol Evol. 2008, 25 (7): 1362-1374. 10.1093/molbev/msn078.
Melton T, Peterson R, Redd AJ, Saha N, Sofro AS, Martinson J, Stoneking M: Polynesian genetic affinities with Southeast Asian populations as identified by mtDNA analysis. Am J Hum Genet. 1995, 57 (2): 403-414.
Friedlaender JS, Friedlaender FR, Reed FA, Kidd KK, Kidd JR, Chambers GK, Lea RA, Loo JH, Koki G, Hodgson JA, et al: The genetic structure of Pacific Islanders. PLoS Genet. 2008, 4 (1): e19-10.1371/journal.pgen.0040019.
Myles S, Hradetzky E, Engelken J, Lao O, Nurnberg P, Trent RJ, Wang X, Kayser M, Stoneking M: Identification of a candidate genetic variant for the high prevalence of type II diabetes in Polynesians. Eur J Hum Genet. 2007, 15 (5): 584-589. 10.1038/sj.ejhg.5201793.
Li X, Monks B, Ge Q, Birnbaum MJ: Akt/PKB regulates hepatic metabolism by directly inhibiting PGC-1[agr] transcription coactivator. Nature. 2007, 447 (7147): 1012-10.1038/nature05861.
Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM: A Cold-Inducible Coactivator of Nuclear Receptors Linked to Adaptive Thermogenesis. 1998, 92 (6): 829-
Rohas LM, St-Pierre J, Uldry M, JÃ¤ger S, Handschin C, Spiegelman BM: A fundamental system of cellular energy homeostasis regulated by PGC-1alpha. PNAS. 2007, 104 (19): 7933-7938. 10.1073/pnas.0702683104.
Soyal S, Krempler F, Oberkofler H, Patsch W: PGC-1alpha: a potent transcriptional cofactor involved in the pathogenesis of type 2 diabetes. Diabetologia. 2006, 49 (7): 1477-1488. 10.1007/s00125-006-0268-6.
Storey KB: Mammalian hibernation. Transcriptional and translational controls. Adv Exp Med Biol. 2003, 543: 21-38.
Choi YS, Hong JM, Lim S, Ko KS, Pak YK: Impaired coactivator activity of the Gly482 variant of peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha) on mitochondrial transcription factor A (Tfam) promoter. Biochem Biophys Res Commun. 2006, 344 (3): 708-712. 10.1016/j.bbrc.2006.03.193.
Ling C, Poulsen P, Carlsson E, Ridderstrale M, Almgren P, Wojtaszewski J, Beck-Nielsen H, Groop L, Vaag A: Multiple environmental and genetic factors influence skeletal muscle PGC-1alpha and PGC-1beta gene expression in twins. J Clin Invest. 2004, 114 (10): 1518-1526.
Andrulionytè L, Zacharova J, Chiasson JL, Laakso M, the S-NSG: Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial. Diabetologia. 2004, 47 (12): 2176-
Zhang SL, Lu WS, Yan L, Wu MC, Xu MT, Chen LH, Cheng H: Association between peroxisome proliferator-activated receptor-gamma coactivator-1alpha gene polymorphisms and type 2 diabetes in southern Chinese population: role of altered interaction with myocyte enhancer factor 2C. Chin Med J (Engl). 2007, 120 (21): 1878-1885.
Bhat A, Koul A, Rai E, Sharma S, Dhar M, Bamezai R: PGC-1α Thr394Thr and Gly482Ser variants are significantly associated with T2DM in two North Indian populations: a replicate case-control study. Human Genetics. 2007, 121 (5): 609-10.1007/s00439-007-0352-0.
Hara K, Tobe K, Okada T, Kadowaki H, Akanuma Y, et al: A genetic variation in the PGC-1 gene could confer insulin resistance and susceptibility to Type II diabetes. Diabetologia. 2002, 45 (5): 740-10.1007/s00125-002-0803-z.
Ek J, Andersen G, Urhammer SA, Gæde PH, Drivsholm T, Borch-Johnsen K, Hansen T, Pedersen O: Mutation analysis of peroxisome proliferator-activated receptor-γ coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to Type II diabetes mellitus. Diabetologia. 2001, 44 (12): 2220-10.1007/s001250100032.
Esterbauer H, Oberkofler H, Linnemayr V, Iglseder B, Hedegger M, Wolfsgruber P, Paulweber B, Fastner G, Krempler F, Patsch W: Peroxisome proliferator-activated receptor-gamma coactivator-1 gene locus: associations with obesity indices in middle-aged women. Diabetes. 2002, 51 (4): 1281-1286. 10.2337/diabetes.51.4.1281.
Barroso I, Luan J, Sandhu M, Franks P, Crowley V, Schafer A, O'Rahilly S, Wareham N: Meta-analysis of the Gly482Ser variant in PPARGC1A in type 2 diabetes and related phenotypes. Diabetologia. 2006, 49 (3): 501-10.1007/s00125-005-0130-2.
Nelson TL, Fingerlin TE, Moss L, Barmada MM, Ferrell RE, Norris JM: The Peroxisome Proliferator-activated Receptor Gamma Coactivator-1 Alpha Gene (PGC-1alpha) is Not Associated with Type 2 Diabetes Mellitus or Body Mass Index Among Hispanic and Non Hispanic Whites from Colorado. Exp Clin Endocrinol Diabetes. 2007, 115 (04): 268-10.1055/s-2007-960495.
Vimaleswaran KS, Radha V, Anjana M, Deepa R, Ghosh S, Majumder PP, Rao MRS, Mohan V: Effect of polymorphisms in the PPARGC1A gene on body fat in Asian Indians. Int J Obes. 2006, 30 (6): 884-10.1038/sj.ijo.0803228.
Lacquemant C, Chikri M, Boutin P, Samson C, Froguel P: No association between the G482S polymorphism of the proliferator-activated receptor-gamma coactivator-1 (PGC-1) gene and Type II diabetes in French Caucasians. Diabetologia. 2002, 45: 602-603. 10.1007/s00125-002-0783-z.
Barroso I, Luan Ja, Middelberg RPS, Harding A-H, Franks PW, Jakes RW, Clayton D, Schafer AJ, O'Rahilly S, Wareham NJ: Candidate Gene Association Study in Type 2 Diabetes Indicates a Role for Genes Involved in Beta-Cell Function as Well as Insulin Action. PLoS Biol. 2003, 1 (1): e20-10.1371/journal.pbio.0000020.
Oberkofler H, Linnemayr V, Weitgasser R, Klein K, Xie M, Iglseder B, Krempler F, Paulweber B, Patsch W: Complex haplotypes of the PGC-1alpha gene are associated with carbohydrate metabolism and type 2 diabetes. Diabetes. 2004, 53 (5): 1385-1393. 10.2337/diabetes.53.5.1385.
Cann HM, de Toma C, Cazes L, Legrand MF, Morel V, Piouffre L, Bodmer J, Bodmer WF, Bonne-Tamir B, Cambon-Thomsen A, et al: A human genome diversity cell line panel. Science. 2002, 296 (5566): 261-262. 10.1126/science.296.5566.261b.
Rosenberg NA: Standardized Subsets of the HGDP-CEPH Human Genome Diversity Cell Line Panel, Accounting for Atypical and Duplicated Samples and Pairs of Close Relatives. Ann Hum Genet. 2006, 70 (6): 841-847. 10.1111/j.1469-1809.2006.00285.x.
World Health Organization: [http://www.who.int]
Duarte NL, Colagiuri S, Palu T, Wang XL, Wilcken DEL: Obesity, Type II diabetes and the Ala54Thr polymorphism of fatty acid binding protein 2 in the Tongan population. Molecular Genetics and Metabolism. 2003, 79 (3): 183-10.1016/S1096-7192(03)00088-X.
Deka R, Xu L, Pal P, Toelupe P, Laumoli T, Xi H, Zhang G, Weeks D, McGarvey S: A tagging SNP in INSIG2 is associated with obesity-related phenotypes among Samoans. BMC Medical Genetics. 2009, 10 (1): 143-10.1186/1471-2350-10-143.
Rush EC, Freitas I, Plank LD: Body size, body composition and fat distribution: comparative analysis of European, Maori, Pacific Island and Asian Indian adults. Br J Nutr. 2009, 102 (4): 632-641. 10.1017/S0007114508207221.
Myles S, Davison D, Barrett J, Stoneking M, Timpson N: Worldwide population differentiation at disease-associated SNPs. BMC Medical Genomics. 2008, 1: 22-10.1186/1755-8794-1-22.
Pickrell JK, Coop G, Novembre J, Kudaravalli S, Li JZ, Absher D, Srinivasan BS, Barsh GS, Myers RM, Feldman MW, et al: Signals of recent positive selection in a worldwide sample of human populations. Genome Research. 2009, 19: 826-837. 10.1101/gr.087577.108.
Blekhman R, Man O, Herrmann L, Boyko AR, Indap A, Kosiol C, Bustamante CD, Teshima KM, Przeworski M: Natural Selection on Genes that Underlie Human Disease Susceptibility. Current Biology. 2008, 18 (12): 883-10.1016/j.cub.2008.04.074.
Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, Boutin P, Vincent D, Belisle A, Hadjadj S, et al: A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature. 2007, 445 (7130): 881-885. 10.1038/nature05616.
Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University and Novartis Institutes of BioMedical Research, Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PIW, Chen H, Roix JJ, Kathiresan S, et al: Genome-Wide Association Analysis Identifies Loci for Type 2 Diabetes and Triglyceride Levels. Science. 2007, 316 (5829): 1331-1336. 10.1126/science.1142358.
Salonen JT, Uimari P, Aalto J-M, Pirskanen M, Kaikkonen J, Todorova B, Hyppnen J, Korhonen V-P, Asikainen J, Devine C, et al: Type 2 Diabetes Whole-Genome Association Study in Four Populations: The DiaGen Consortium. Am J Hum Genet. 2007, 81 (2): 338-345. 10.1086/520599.
Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, Timpson NJ, Perry JR, Rayner NW, Freathy RM, et al: Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science. 2007, 316 (5829): 1336-1341. 10.1126/science.1142364.
Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, Erdos MR, Stringham HM, Chines PS, Jackson AU, et al: A Genome-Wide Association Study of Type 2 Diabetes in Finns Detects Multiple Susceptibility Variants. Science. 2007, 316 (5829): 1341-1345. 10.1126/science.1142382.
The Wellcome Trust Case Control Consortium: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007, 447 (7145): 661-678. 10.1038/nature05911.
Hofker M, Wijmenga C: A supersized list of obesity genes. Nat Genet. 2009, 41 (2): 139-10.1038/ng0209-139.
Furusawa T, Naka I, Yamauchi T, Natsuhara K, Kimura R, Nakazawa M, Ishida T, Inaoka T, Matsumura Y, Ataka Y, et al: The Q223R polymorphism in LEPR is associated with obesity in Pacific Islanders. Human Genetics. 2010, 127 (3): 287-10.1007/s00439-009-0768-9.
Rajeevan H, Cheung KH, Gadagkar R, Stein S, Soundararajan U, Kidd JR, Pakstis AJ, Miller PL, Kidd KK: ALFRED: an allele frequency database for microevolutionary studies. Evol Bioinform Online. 2005, 1: 1-10.
Scuteri A, Sanna S, Chen W-M, Uda M, Albai G, Strait J, Najjar S, Nagaraja R, OrrÃ° M, Usala G, et al: Genome-Wide Association Scan Shows Genetic Variants in the FTO Gene Are Associated with Obesity-Related Traits. PLoS Genet. 2007, 3 (7): e115-10.1371/journal.pgen.0030115.
Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, Perry JR, Elliott KS, Lango H, Rayner NW, et al: A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007, 316 (5826): 889-894. 10.1126/science.1141634.
Dina C, Meyre D, Gallina S, Durand E, Korner A, Jacobson P, Carlsson L, Kiess W, Vatin V, Lecoeur C, et al: Variation in FTO contributes to childhood obesity and severe adult obesity. Nature Genetics. 2007, 39: 724-726. 10.1038/ng2048.
Ohashi J, Naka I, Kimura R, Natsuhara K, Yamauchi T, Furusawa T, Nakazawa M, Ataka Y, Patarapotikul J, Nuchnoi P, et al: FTO polymorphisms in oceanic populations. J Hum Genet. 2007, 52 (12): 1031-1035. 10.1007/s10038-007-0198-2.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/12/10/prepub
We are deeply grateful to all participants for their cooperation in providing blood or saliva samples for genotyping. We thank Drs. Viliami Tangi, Ministry of Health, Kingdom of Tonga and Taniela Palu, Diabetes Clinic, Kingdom of Tonga for their understanding and permission to conduct this research; Te Iwi o Rakaipaaka Incorporated and the Ngati Rakaipaaka community of Nuhaka for their participation; Dinusha Bandara, Michael Dannemann and Roger Mundry for statistical advice; and Don Stewart and members of the Department of Biology at Acadia University for use of laboratory facilities. Research supported by the Max Planck Society, ESR Ltd and the United States Department of Agriculture.